AIM: This study aimed to elucidate the gene and lipid profiles of children clinically diagnosed with familial hypercholesterolemia (FH). METHODS: A total of 21 dyslipidemia-related Mendelian genes, including FH causative genes (LDLR, APOB, and PCSK9) and LDL-altering genes (APOE, LDLRAP1, and ABCG5/8), were sequenced in 33 Japanese children (mean age, 9.7±4.2 years) with FH from 29 families. RESULTS: Fifteen children (45.5%) with pathogenic variants in LDLR (eight different heterozygous variants) and one child (3.0%) with the PCSK9 variant were found. Among 17 patients without FH causative gene variants, 3 children had variants in LDL-altering genes, an APOE variant and two ABCG8 variants. The mean serum total cholesterol (280 vs 246 mg/dL), LDL-cholesterol (LDL-C, 217 vs 177 mg/dL), and non-HDL cholesterol (228 vs 188 mg/dL) levels were significantly higher in the pathogenic variant-positive group than in the variant-negative group. In the variant-positive group, 81.3% of patients had LDL-C levels ≥ 180 mg/dL but 35.3% in the variant-negative group. The mean LDL-C level was significantly lower in children with missense variants, especially with the p.Leu568Val variant, than in children with other variants in LDLR, whereas the LDL-altering variants had similar effects on the increase in serum LDL-C to LDLR p.Leu568Val. CONCLUSION: Approximately half of the children clinically diagnosed with FH had pathogenic variants in FH causative genes. The serum LDL-C levels tend to be high in FH children with pathogenic variations, and the levels are by the types of variants. Genetic analysis is useful; however, further study on FH without any variants is required.
AIM: This study aimed to elucidate the gene and lipid profiles of children clinically diagnosed with familial hypercholesterolemia (FH). METHODS: A total of 21 dyslipidemia-related Mendelian genes, including FH causative genes (LDLR, APOB, and PCSK9) and LDL-altering genes (APOE, LDLRAP1, and ABCG5/8), were sequenced in 33 Japanese children (mean age, 9.7±4.2 years) with FH from 29 families. RESULTS: Fifteen children (45.5%) with pathogenic variants in LDLR (eight different heterozygous variants) and one child (3.0%) with the PCSK9 variant were found. Among 17 patients without FH causative gene variants, 3 children had variants in LDL-altering genes, an APOE variant and two ABCG8 variants. The mean serum total cholesterol (280 vs 246 mg/dL), LDL-cholesterol (LDL-C, 217 vs 177 mg/dL), and non-HDL cholesterol (228 vs 188 mg/dL) levels were significantly higher in the pathogenic variant-positive group than in the variant-negative group. In the variant-positive group, 81.3% of patients had LDL-C levels ≥ 180 mg/dL but 35.3% in the variant-negative group. The mean LDL-C level was significantly lower in children with missense variants, especially with the p.Leu568Val variant, than in children with other variants in LDLR, whereas the LDL-altering variants had similar effects on the increase in serum LDL-C to LDLR p.Leu568Val. CONCLUSION: Approximately half of the children clinically diagnosed with FH had pathogenic variants in FH causative genes. The serum LDL-C levels tend to be high in FH children with pathogenic variations, and the levels are by the types of variants. Genetic analysis is useful; however, further study on FH without any variants is required.
Authors: Philippa J Talmud; Sonia Shah; Ros Whittall; Marta Futema; Philip Howard; Jackie A Cooper; Seamus C Harrison; Kawah Li; Fotios Drenos; Frederik Karpe; H Andrew W Neil; Olivier S Descamps; Claudia Langenberg; Nicholas Lench; Mika Kivimaki; John Whittaker; Aroon D Hingorani; Meena Kumari; Steve E Humphries Journal: Lancet Date: 2013-02-22 Impact factor: 79.321
Authors: M Chmara; B Wasag; M Zuk; J Kubalska; A Wegrzyn; M Bednarska-Makaruk; E Pronicka; H Wehr; J C Defesche; A Rynkiewicz; J Limon Journal: J Appl Genet Date: 2010 Impact factor: 3.240
Authors: Itziar Lamiquiz-Moneo; Lucía Baila-Rueda; Ana M Bea; Rocío Mateo-Gallego; Sofía Pérez-Calahorra; Victoria Marco-Benedí; Antonio Martín-Navarro; Emilio Ros; Montserrat Cofán; José Carlos Rodríguez-Rey; Miguel Pocovi; Ana Cenarro; Fernando Civeira Journal: J Clin Lipidol Date: 2017-10-04 Impact factor: 4.766
Authors: Anna M Bennet; Emanuele Di Angelantonio; Zheng Ye; Frances Wensley; Anette Dahlin; Anders Ahlbom; Bernard Keavney; Rory Collins; Björn Wiman; Ulf de Faire; John Danesh Journal: JAMA Date: 2007-09-19 Impact factor: 56.272
Authors: T L Innerarity; K H Weisgraber; K S Arnold; R W Mahley; R M Krauss; G L Vega; S M Grundy Journal: Proc Natl Acad Sci U S A Date: 1987-10 Impact factor: 11.205
Authors: T Maruyama; Y Miyake; S Tajima; M Harada-Shiba; T Yamamura; M Tsushima; B Kishino; Y Horiguchi; T Funahashi; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 1995-10 Impact factor: 8.311